ZIM Laboratories Limited.

ZIM Laboratories Limited, established in 1984, is a research-driven pharmaceutical company headquartered in Nagpur, Maharashtra, India. The company specializes in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products, focusing on oral solid dosage forms such as tablets, capsules, and oral thin films. ZIM Laboratories offers therapeutics across various therapeutic areas, including urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements.

The company is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 541400 and on the National Stock Exchange of India (NSE) under the symbol ZIMLAB. As of March 13, 2026, ZIM Laboratories' stock price was ₹66.69, reflecting a 2.84% increase from the previous close. The company has a paid-up capital of ₹487,258,140 and an authorized capital of ₹750,000,000. ZIM Laboratories employs approximately 577 individuals, indicating a robust workforce dedicated to its operations.

ZIM Laboratories operates manufacturing facilities in Nagpur, Maharashtra, India. The company specializes in the production of oral solid dosage forms, including tablets, capsules, dry syrups, and oral thin films. These facilities are equipped with advanced technology platforms such as multi-particulates (pellets), taste masking, innovative granulation (direct compression granules), and orally disintegrating strips (thin films). The manufacturing plants adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical products.

The leadership team at ZIM Laboratories is headed by Executive Chairman and Managing Director, Anwar Siraj Daud, who has been with the company since 2002. The Chief Financial Officer is Shyam Mohan Patro, who joined the company in April 2019. Other key executives include Niraj Pukhraj Dhadiwal, Director of Business Development and Executive Director since 2013; Zulfiquar Murtaza Kamal, Director of Finance and Executive Director since 2012; and Prakash Pralhadrao Sapkal, Head of ODS Business, Formulations of Domestic, ROW, and Emerging Markets & Director since 2013. This experienced leadership team drives the company's strategic initiatives and operational excellence.

ZIM Laboratories has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has received approval from the Central Drugs Standard Control Organization (CDSCO) in India for its novel Fixed Dose Combination formulation: Naproxen Delayed Release and Esomeprazole Capsules (375 mg/500 mg + 20 mg/20 mg). This product, developed using ZIM's proprietary drug delivery systems, is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as reducing the risk of NSAID-associated gastric and duodenal ulcers. The approval, granted on March 12, 2025, strengthens ZIM's presence in the pain management and gastro-protective therapeutic areas.

In the United States, ZIM Laboratories has registered its manufacturing facilities with the Food and Drug Administration (FDA), enabling the export of its products to the U.S. market. The company has also filed Abbreviated New Drug Applications (ANDAs) for several products, seeking approval for marketing in the U.S. In the European Union, ZIM Laboratories has obtained European Union Good Manufacturing Practice (EU GMP) certification, ensuring compliance with EU standards for pharmaceutical manufacturing. The company has also filed for marketing authorizations in various EU member states, facilitating access to these markets. In Australia, ZIM Laboratories has established a subsidiary, ZIMTAS Pty Ltd, incorporated in December 2022, to handle product registrations and marketing and distribution initiatives in Australia and New Zealand.

ZIM Laboratories has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company has established subsidiaries such as ZIM Laboratories FZE in Sharjah, UAE, and ZIMTAS Pty Ltd in Australia, to enhance its presence in these regions. These subsidiaries focus on business development, marketing, product registrations, and distribution initiatives, enabling ZIM Laboratories to tap into new markets and strengthen its global presence. Additionally, the company's adherence to World Health Organization (WHO) prequalification standards facilitates access to various international markets, ensuring the quality and safety of its products.

ZIM Laboratories has adopted a diversified geographic strategy to mitigate concentration risk and capitalize on growth opportunities across different regions. The establishment of subsidiaries in strategic locations, including the UAE, Australia, and the EU, reflects the company's commitment to expanding its global footprint. This approach allows ZIM Laboratories to better serve international clients, comply with local regulations, and foster closer relationships with customers and partners worldwide. The company's focus on both developed and emerging markets demonstrates a balanced approach to growth and risk management.

ZIM Laboratories has registered its manufacturing facilities with the FDA, enabling the export of its products to the U.S. market. The company has filed ANDAs for several products, seeking approval for marketing in the U.S. These filings indicate ZIM Laboratories' commitment to expanding its presence in the U.S. pharmaceutical market. The company's adherence to FDA regulations and standards underscores its dedication to quality and compliance in its manufacturing processes.

ZIM Laboratories has obtained EU GMP certification, ensuring compliance with European standards for pharmaceutical manufacturing. This certification facilitates the company's access to the European market, allowing it to market and distribute its products within the EU. The company's adherence to WHO prequalification standards further demonstrates its commitment to maintaining high-quality manufacturing practices, which is essential for accessing various international markets.

In India, ZIM Laboratories holds manufacturing licenses issued by the CDSCO, authorizing it to produce pharmaceutical products for domestic and export markets. The company's compliance with Indian regulatory standards ensures the safety, efficacy, and quality of its products. ZIM Laboratories has also obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating the export of its products to various international markets. These regulatory approvals reflect the company's commitment to adhering to national and international standards in its manufacturing and export operations.

On March 12, 2025, ZIM Laboratories received approval from the CDSCO for its novel Fixed Dose Combination formulation: Naproxen Delayed Release and Esomeprazole Capsules (375 mg/500 mg + 20 mg/20 mg). This approval strengthens the company's presence in the pain management and gastro-protective therapeutic areas. There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to ZIM Laboratories by the FDA or other regulatory bodies. The company's adherence to regulatory standards and proactive approach to compliance contribute to its positive regulatory standing.

ZIM Laboratories operates in a competitive pharmaceutical industry, with several key players in the generic pharmaceutical and nutraceutical sectors. While specific market share data is not publicly available, ZIM Laboratories' focus on differentiated drug delivery solutions, such as its proprietary oral thin film technology, positions it uniquely in the market. The company's diverse product portfolio across various therapeutic areas, including urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements, allows it to cater to a broad patient base. ZIM Laboratories' strategic expansion into emerging markets further enhances its competitive position.

ZIM Laboratories' key differentiators include its focus on research-driven pharmaceutical development, proprietary drug delivery technologies, and a diverse product portfolio across multiple therapeutic areas. The company's in-house R&D capabilities enable it to offer non-infringing drug delivery solutions based on process technologies, enhancing patient compliance and reducing treatment costs. Additionally, ZIM Laboratories' commitment to quality is demonstrated through its adherence to international standards, including WHO prequalification and EU GMP certifications. The establishment of subsidiaries in strategic locations worldwide reflects the company's dedication to expanding its global presence and serving international clients effectively.

ZIM Laboratories' current strategic direction focuses on the development and supply of differentiated generic pharmaceutical and nutraceutical